Brief Title
Stem Cells for Bronchopulmonary Dysplasia
Official Title
Stem Cells for Bronchopulmonary Dysplasia: a Cohort Study
Brief Summary
Very preterm infants are at high risk to develop to bronchopulmonary dysplasia (BPD) for the lack of effective measures to prevent or ameliorate this common and serious disorder. BPD remains a major cause of mortality and lifelong morbidity in preterm infants
Detailed Description
Several studies have shown that transplantation of mesenchymal stem cells (MSCs) in immunocompetent animals attenuates lung injury, such as impaired alveolarization, inflammatory response, increased apoptosis, and fibrosis. Human umbilical cord blood (hUCB) is considered a better source of MSCs because of their ready availability and greater proliferative capacity and less antigenicity than other cell types. transplantation of hUCB-derived MSCs should be effective in treating BPD. The safety and efficacy of MSC transplantation for prevention of BPD has not been tested previously, however.
Study Phase
Early Phase 1
Study Type
Interventional
Primary Outcome
death
Secondary Outcome
Bayley Scales of Infant Development
Condition
Bronchopulmonary Dysplasia
Intervention
transplantation of mesenchymal stem cell
Study Arms / Comparison Groups
transplantation of mesenchymal stem cell
Description: transplantation of mesenchymal stem cell will be given to the infants with BPD.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
100
Start Date
November 1, 2017
Completion Date
December 30, 2022
Primary Completion Date
December 30, 2022
Eligibility Criteria
Inclusion Criteria: - diagnosed with BPD Exclusion Criteria: - parents' rejection
Gender
All
Ages
1 Month - 3 Months
Accepts Healthy Volunteers
No
Contacts
, ,
Location Countries
China
Location Countries
China
Administrative Informations
NCT ID
NCT03378063
Organization ID
stem cell for BPD
Responsible Party
Principal Investigator
Study Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Collaborators
Children's Hospital of Chongqing Medical University
Study Sponsor
, ,
Verification Date
February 2021